|
1
|
Danaei G, Finucane MM, Lin JK, Singh GM,
Paciorek CJ, Cowan MJ, Farzadfar F, Stevens GA, Lim SS, Riley LM,
et al: National, regional, and global trends in systolic blood
pressure since 1980: Systematic analysis of health examination
surveys and epidemiological studies with 786 country-years and 5·4
million participants. Lancet. 377:568–577. 2011.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lee Yh, Cho Y, Lee BW, Park CY, Lee DH,
Cha BS and Rhee EJ: Nonalcoholic fatty liver disease in diabetes.
Part I: Epidemiology and diagnosis. Diabetes Metab J. 43:31–45.
2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Adams LA, Harmsen S, St Sauver JL,
Charatcharoenwitthaya P, Enders FB, Therneau T and Angulo P:
Nonalcoholic fatty liver disease increases risk of death among
patients with diabetes: A community-based cohort study. Am J
Gastroenterol. 105:1567–1573. 2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Hazlehurst JM, Woods C, Marjot T, Cobbold
JF and Tomlinson JW: Non-alcoholic fatty liver disease and
diabetes. Metabolism. 65:1096–1108. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Garcia-Compean D, Jacquez-Quintana JO,
Gonzalez-Gonzalez JA and Maldonado-Garza H: Liver cirrhosis and
diabetes: Risk factors, pathophysiology, clinical implications and
management. World J of Gastroenterol. 15:280–288. 2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ingaramo PI, Ronco MT, Francés DE, Monti
JA, Pisani GB, Ceballos MP, Galleano M, Carrillo MC and Carnovale
CE: Tumor necrosis factor alpha pathways develops liver apoptosis
in type 1 diabetes mellitus. Mol Immunol. 48:1397–1407.
2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Pan L, Weng H, Li H, Liu Z, Xu Y, Zhou C,
Lu X, Su X, Zhang Y and Chen D: Therapeutic effects of bupleurum
polysaccharides in streptozotocin induced diabetic mice. PLoS One.
10(e0133212)2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Schmidt-Arras D and Rose-John S: IL-6
pathway in the liver: From physiopathology to therapy. J Hepatol.
64:1403–1415. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Liaskou E, Zimmermann HW, Li KK, Oo YH,
Suresh S, Stamataki Z, Qureshi O, Lalor PF, Shaw J, Syn WK, et al:
Monocyte subsets in human liver disease show distinct phenotypic
and functional characteristics. Hepatology. 57:385–398.
2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bilal HM, Riaz F, Munir K, Saqib A and
Sarwar MR: Histological changes in the liver of diabetic rats: A
review of pathogenesis of nonalcoholic fatty liver disease in type
1 diabetes mellitus. Cogent Med. 3(1)2016.
|
|
11
|
Vongsak B, Kongkiatpaiboon S, Jaisamut S
and Konsap K: Comparison of active constituents, antioxidant
capacity, and α-glucosidase inhibition in Pluchea indica
leaf extracts at different maturity stages. Food Biosci. 25:68–73.
2018.
|
|
12
|
Noridayu AR, Hii YF, Faridah A, Khozirah S
and Lajis N: Antioxidant and antiacetylcholinesterase activities of
Pluchea indica Less. Int Food Res J. 18:925–929. 2011.
|
|
13
|
Buapool D, Mongkol N, Chantimal J,
Roytrakul S, Srisook E and Srisook K: Molecular mechanism of
anti-inflammatory activity of Pluchea indica leaves in
macrophages RAW 264.7 and its action in animal models
ofinflammation. J Ethnopharmacol. 146:495–504. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Roslida AH, Erazuliana AK and Zuraini A:
Anti-inflammatory and antinociceptive activities of the ethanolic
extract of Pluchea indica (L) less leaf. Pharmacologyonline.
2:349–360. 2008.
|
|
15
|
Widyawati PS, Budianta TDW, Gunawan DI and
Wongso RS: Evaluation antidiabetic activity of various leaf
extracts of Pluchea indica less. Int J Pharmacogn Phytochem
Res. 7:597–603. 2015.
|
|
16
|
Pramanik KC, Bhattacharya P, Biswas R,
Bandyopadhyay D, Mishra M and Chatterjee TK: Hypoglycemic and
antihyperglycemic activity of leaf extract of Pluchea indica
Less. Orient Pharm Exp Med. 6:232–236. 2006.
|
|
17
|
Nopparat J, Nualla-Ong A and Phongdara A:
Ethanolic extracts of Pluchea indica (L.) leaf pretreatment
attenuates cytokine-induced β-cell apoptosis in multiple low-dose
streptozotocin-induced diabetic mice. PLoS One.
14(e0212133)2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Landin-Olsson M: Latent autoimmune
diabetes in adults. Ann NY Acad Sci. 958:112–116. 2002.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Eleazu CO, Eleazu KC, Chukwuma S and
Essien UN: Review of the mechanism of cell death resulting from
streptozotocin challenge in experimental animals, its practical use
and potential risk to humans. J Diabetes Metab Disord.
12(60)2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tesch GH and Allen TJ: Rodent models of
streptozotocin-induced diabetic nephropathy. Nephrology.
12:261–266. 2007.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Furman BL: Streptozotocin-induced diabetic
models in mice and tats. Curr Protoc Pharmacol. 70:1–20. 2015.
|
|
22
|
Yu W, Zha W, Guo S, Cheng H, Wu J and Liu
C: Flos puerariae extract prevents myocardial apoptosis via
attenuation oxidative stress in streptozotocin-induced diabetic
mice. PLoS One. 9(e98044)2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Gallol LE and Mohamed FH:
Immunomorphometric variations of sustentacular cells of the male
viscacha adrenal medulla during the annual reproductive cycle.
Effects of androgens and melatonin. Acta Histochem. 120:363–372.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Palsamy P, Sivakumar S and Subramanian S:
Resveratrol attenuates hyperglycemia-mediated oxidative stress,
proinflammatory cytokines and protects hepatocytes ultrastructure
in streptozotocin-nicotinamide-induced experimental diabetic rats.
Chem Biol Interact. 186:200–210. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Manna P, Das J, Ghosh J and Sil PC:
Contribution of type 1 diabetes to rat liver dysfunction and
cellular damage via activation of NOS, PARP, IkappaB
alpha/NF-kappaB, MAPKs, and mitochondria-dependent pathways:
Prophylactic role of arjunolic acid. Free Radic Biol Med.
48:1465–1484. 2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Dongiovanni P, Anstee QM and Valenti L:
Genetic predisposition in NAFLD and NASH: impact on severity of
liver disease and response to treatment. Curr Pharm Des.
19:5219–5238. 2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Sirichaiwetchakoon K, Lowe GM, Thumanu K
and Eumkeb G: The Effect of Pluchea indica (L.) Less. Tea on
Adipogenesis in 3T3-L1 Adipocytes and Lipase Activity. Evid Based
Complement Alternat Med. 2018(4108787)2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ruan J, Li Z, Yan J, Huang P, Yu H, Han L,
Zhang Y and Wang T: Bioactive constituents from the aerial parts of
Pluchea indica less. Molecules. 23(pii:
E2104)2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Mukhopadhyay P and Prajapati AK: Quercetin
in anti-diabetic research and strategies for improved quercetin
bioavailability using polymer-based carriers-a review. RSC
Advances. 5:97547–97562. 2015.
|
|
30
|
Jeong SM, Kang MJ, Choi HN, Kim JH and Kim
JI: Quercetin ameliorates hyperglycemia and dyslipidemia and
improves antioxidant status in type 2 diabetic db/db mice. Nutr Res
Pract. 6:201–207. 2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yazgan UC, Tasdemir E, Bilgin HM, Obay BD,
Sermet A and Elbey B: Comparison of the anti-diabetic effects of
resveratrol, gliclazide and losartan in streptozotocin-induced
experimental diabetes. Arch Physiol Biochem. 121:157–161.
2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Arsiningtyas IS, Gunawan-Puteri MD, Kato E
and Kawabata J: Identification of α-glucosidase inhibitors from the
leaves of Pluchea indica (L.) Less., a traditional
Indonesian herb: Promotion of natural product use. Nat Prod Res.
28:1350–1353. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ohno T, Horio F, Tanaka S, Terada M,
Namikawa T and Kitoh J: Fatty liver and hyperlipidemia in IDDM
(insulin-dependent diabetes mellitus) of streptozotocin-treated
shrews. Life Sci. 66:125–131. 2002.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Chatrath H, Vuppalanchi R and Chalasani N:
Dyslipidemia in patients with nonalcoholic fatty liver disease.
Semin Liver Dis. 32:22–29. 2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Yang DK and Kang HS: Anti-diabetic effect
of cotreatment with quercetin and resveratrol in
streptozotocin-induced diabetic rats. Biomol Ther. 26:130–138.
2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Palsamy P and Subramanian S: Ameliorative
potential of resveratrol on proinflammatory cytokines,
hyperglycemia mediated oxidative stress, and pancreatic beta-cell
dysfunction in streptozotocin-nicotinamide-induced diabetic rats. J
Cell Physiol. 224:423–432. 2010.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhan YT and An W: Roles of liver innate
immune cells in nonalcoholic fatty liver disease. World J
Gastroenterol. 16:4652–4660. 2010.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Wallenius V, Wallenius K, Ahrén B, Rudling
M, Carlsten H, Dickson SL, Ohlsson C and Jansson JO:
Interleukin-6-deficient mice develop mature-onset obesity. Nat Med.
8:75–79. 2002.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Matthews VB, Allen TL, Risis S, Chan MHS,
Henstridge DC, Watson N, Zaffino LA, Babb JR, Boon J, Meikle PJ, et
al: Interleukin-6-deficient mice develop hepatic inflammation and
systemic insulin resistance. Diabetologia. 53:2431–2441.
2010.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Kolios G, Valatas V and Kouroumalis E:
Role of Kupffer cells in the pathogenesis of liver disease. World J
Gastroenterol. 12:7413–7420. 2006.PubMed/NCBI View Article : Google Scholar
|
